Rodman & Renshaw Initiates Coverage on OpGen Inc(NASDAQ:OPGN). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Jun 29, 2016.
OpGen Inc (OPGN) made into the market gainers list on Fridays trading session with the shares advancing 3.95% or 0.06 points. Due to strong positive momentum, the stock ended at $1.58, which is also near the day’s high of $1.6293. The stock began the session at $1.51 and the volume stood at 50,073 shares. The 52-week high of the shares is $4.43 and the 52 week low is $1.02. The company has a current market capitalization of $20 M and it has 1,25,81,790 shares in outstanding.
OpGen Inc(OPGN) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.36.
Several Insider Transactions has been reported to the SEC. On May 23, 2016, Kevin Krenitsky (President) purchased 43,716 shares at $0.00 per share price.Also, On May 23, 2016, Capital, Llc Jven (10% owner) purchased 874,317 shares at $0.00 per share price.On May 23, 2016, Evan/ Fa Jones (CEO) purchased 874,317 shares at $0.00 per share price, according to the Form-4 filing with the securities and exchange commission.
OpGen, Inc. is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping physicians improve patient outcomes by providing more rapid information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics. Its QuickFISH® products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Clinical laboratory services utilize the Acuitas® products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis and Acuitas Lighthouse™ bioinformatics system designed to detect, type, track and trend antibiotic resistant organisms in real-time. Learn more at www.opgen.com